Navigation Links
Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
Date:1/5/2012

SOUTH SAN FRANCISCO, Calif., Jan. 5, 2012 /PRNewswire/ -- Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced that Pfizer Inc. has initiated a Phase 1 clinical trial for PF-05280602, an investigational proprietary, engineered variant of recombinant human Factor VIIa developed by Catalyst Biosciences.  PF-05280602 has been engineered to provide improved acute and prophylactic treatment for hemophilia A & B patients with inhibitors.  The IND filing and initiation of the Phase 1 clinical trial triggered additional milestone payments of $7.0 million payable to Catalyst by Pfizer under the terms of their research and license agreement. 

"We are very excited to see the lead candidate from Catalyst's hemostasis franchise advance into human clinical trials," said Nassim Usman, Ph.D., Catalyst's CEO.  "In parallel, Catalyst is independently achieving significant progress in engineering next-generation recombinant human Factor IX and Xa variants with highly differentiated advantages for the treatment of acute and prophylactic bleeding disorders, including hemophilia and non-hemophilia indications.  We are diligently executing on our goal of expanding Catalyst's high-value pipeline of novel engineered proteases." 

In June 2009 Catalyst and Wyeth LLC, now a wholly owned subsidiary of Pfizer Inc., formed an exclusive, worldwide collaboration for the discovery, development and commercialization of improved, second-generation Factor VIIa products.  Total payments under the collaboration, including an upfront payment of $21 million, ongoing research funding and milestone payments, could exceed $500 million, exclusive of double-digit royalty payments. 

About Catalyst Biosciences 

Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases that ta
'/>"/>

SOURCE Catalyst Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... International Inc. (NYSE: MTD ) today announced second ... , Sales in local currency increased 3% ... sales decreased 4% as currency reduced sales growth by ... diluted share as reported (EPS) were $2.73, compared with ... , an increase of 9% over the prior-year ...
(Date:7/30/2015)... 30, 2015  ResMed Inc. (NYSE: RMD ) ... 2015.  Revenue for the quarter was $453.1 million, a ... 30, 2014 (a 17 percent increase on a constant ... the quarter ended June 30, 2014.  Diluted earnings per ... quarter ended June 30, 2014.  The ...
(Date:7/30/2015)... -- Today we bring you a special edition of #MedicareMonday on Medicare,s 50 th ... our Medicare resources and continue highlighting the success of the prescription drug benefit, commonly ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
... 4, 2007 - Molecular Insight,Pharmaceuticals, Inc. (NASDAQ: ... the results of several preclinical studies at,the ... Nuclear Medicine (SNM) in,Washington, D.C. The presentations ... clinical-stage, targeted,radiotherapeutic candidate for the treatment of ...
... ZymoGenetics,Inc. today announced that interim findings were presented ... B-cell chronic,lymphocytic leukemia (B-CLL) at the American Society ... included intravenous,administration of higher doses than had been ... was well-tolerated and biologically,active at all dose levels ...
Cached Medicine Technology:Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,at Society Of Nuclear Medicine 2007 Annual Meeting 2Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,at Society Of Nuclear Medicine 2007 Annual Meeting 3Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,at Society Of Nuclear Medicine 2007 Annual Meeting 4ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 2ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 3
(Date:8/1/2015)... ... ... March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery ... off Springer Mountain and heading north. Since that day, Phil has hiked over 1400 miles ... by friends and family. He visited CCAR and left an inspirational message to his ...
(Date:7/31/2015)... ... August 01, 2015 , ... The Honor Society of Nursing, ... on the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, Puerto Rico. ... this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel Development, Unit ...
(Date:7/31/2015)... ... 31, 2015 , ... Recently touted by Becker’s Healthcare as ... analytics , Jvion continues to disrupt the predictive analytic and big data market ... and population level illness to drive prevention and better health outcomes. Most recently, ...
(Date:7/31/2015)... ... ... There’s no better way to enjoy the summer weather than by being outside ... making July the most appropriate to be National Hot Dog Month. King Kullen honors ... next cookout different than the ones in the past. Celebrate National Hot Dog Month ...
(Date:7/31/2015)... ... ... M3 USA MDLinx.com, source of the Smartest Doc Board Exam Prep in ... The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an already robust selection of ... easy and painless. MDLinx offers thousands of board-exam style questions and exam-specific content ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3
... 2011 -- A research group led by a professor from ... this week as one of the first three centers chosen ... called the Centers for Research Excellence, known in brief ... national program and will eventually include 30 research centers operating ...
... brought into hospital with alcohol-related illnesses or injuries but how ... A researcher at The University of Nottingham is launching ... student nurses are receiving the alcohol training and education which ... news that alcohol-related admissions to hospital have topped one million ...
... -- Four of the most frequently prescribed epilepsy drugs appear to ... pregnancy, a new study finds. And the higher the ... in the June 6 online edition of The Lancet Neurology ... as the choice of drug," the authors said in a journal ...
... new targeted therapy for prostate cancer halts tumor growth ... to hormone therapy, a new study finds. The results ... Annual Meeting in Boston. "This targeted therapy may ... of men with advanced, hormone-refractory prostate cancer," said lead ...
... By Amanda Gardner HealthDay Reporter , SUNDAY, ... lung cancer only take four courses of two chemotherapy drugs ... of those drugs may delay return of the deadly disease, ... but Spanish scientists report that staying on Alimta (pemextrexed) delayed ...
... at the Indiana University School of Medicine have discovered ... pain. Unlike current treatments this peptide does not ... memory loss, or depression, according to an article in ... The peptide, CBD3, has been shown in mice ...
Cached Medicine News:Health News:Group led by Hebrew University professor chosen as Israeli Center for Research Excellence 2Health News:Are frontline nurses prepared for alcohol-related cases? 2Health News:Epilepsy Drugs' Risk of Birth Defects May Be Dose-Dependent 2Health News:Epilepsy Drugs' Risk of Birth Defects May Be Dose-Dependent 3Health News:Targeted cancer therapy kills prostate tumor cells 2Health News:Taking Chemo Drug Continuously Delayed Lung Cancer's Return 2Health News:Taking Chemo Drug Continuously Delayed Lung Cancer's Return 3Health News:Indiana University neuroscientists map a new target to wipe pain away 2
For the quantitative determination of high density lipoprotein (HDL) in human serum....
... Intended for the ... in plasma. Two vials, ... Enzymatic, alphaketoglutarate. Uses NADPH ... other plasma compounds. Reaction: ...
... The Proteomeworks system is an ... technologies that enables protein function ... sample preparation, 2-D electrophoresis, staining, ... excision, automated protein digestion, mass ...
Storage temperature: 2 - 8C, linearity: 0 - 700 mg/dL, expected values: 30 - 780 mg/dL. Available with calibrator and number of tests 110....
Medicine Products: